Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2016, Article ID 8034832, 5 pages
http://dx.doi.org/10.1155/2016/8034832
Case Report

Pulmonary Fibrosis after Pegylated Liposomal Doxorubicin in Elderly Patient with Cutaneous Angiosarcoma

Medical Oncology Unit, Sant’Andrea Hospital, Via di Grottarossa 1035-39, 00189 Rome, Italy

Received 19 October 2015; Revised 30 December 2015; Accepted 3 January 2016

Academic Editor: Annekathryn Goodman

Copyright © 2016 Marco Mazzotta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. J. Young, N. J. Brown, M. W. Reed, D. Hughes, and P. J. Woll, “Angiosarcoma,” The Lancet Oncology, vol. 11, no. 10, pp. 983–991, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. K. M. Skubitz, “Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma,” Cancer Investigation, vol. 21, no. 2, pp. 167–176, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. Doxorubicin, Pegylated Liposomal Monograph, December 2015, http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Doxorubicinpegylatedliposomal_monograph_1Jan07.pdf.
  4. J. Huober, O. Schoch, A. Templeton, C. Spirig, and B. Thürlimann, “Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer,” Chemotherapy, vol. 56, no. 1, pp. 69–70, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Mark and B. Thürlimann, “Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission,” Medical Oncology, vol. 29, no. 3, pp. 1477–1478, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Inaba, T. Arimoto, M. Hoya et al., “Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer,” Medical Oncology, vol. 29, no. 2, pp. 1255–1257, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. N. S. Nevadunsky, C. Mbagwu, N. Mizrahi, E. Burton, and G. L. Goldberg, “Pulmonary fibrosis after pegylated liposomal doxorubicin in a patient with uterine papillary serous carcinoma,” Journal of Clinical Oncology, vol. 31, no. 10, pp. e167–e169, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. U. Wollina, J. Füller, T. Graefe, M. Kaatz, and E. Lopatta, “Angiosarcoma of the scalp: treatment with liposomal doxorubicin and radiotherapy,” Journal of Cancer Research and Clinical Oncology, vol. 127, no. 6, pp. 396–399, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Eiling, S. Lischner, J.-O. Busch, D. Rothaupt, E. Christophers, and A. Hauschild, “Complete remission of a radio-resistant cutaneous angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin,” British Journal of Dermatology, vol. 147, no. 1, pp. 150–153, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. N. A. Barber and A. K. Ganti, “Pulmonary toxicities from targeted therapies: a review,” Targeted Oncology, vol. 6, no. 4, pp. 235–243, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Nemery, A. Bast, J. Behr et al., “Interstitial lung disease induced by exogenous agents: factors governing susceptibility,” European Respiratory Journal, vol. 18, no. 32, pp. 30S–42S, 2001. View at Google Scholar · View at Scopus